+ Filter
Loading...
Custom Services order now ship next day

Anti-FLT1 Recombinant Antibody Products

Loading...

Anti-FLT1 Products

View More Products

Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag

More Infomation

Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us

For Research Use Only. Not For Clinical Use.


Creative Biolabs is at the forefront of developing high-quality anti-FLT1 recombinant antibody products, meticulously engineered to meet the rigorous demands of global research and therapeutic development. Our innovative solutions empower scientists worldwide with superior tools for advancing critical studies in angiogenesis, cancer, and various vascular-related diseases, ensuring reliable and reproducible results for groundbreaking discoveries.

FLT1: a Pivotal Target for Angiogenesis-Related Therapies

Fms-like tyrosine kinase 1 (FLT1), also known as VEGFR1, is a key receptor for vascular endothelial growth factor (VEGF) family members, playing a crucial role in angiogenesis and vascular development. Extensive research highlights its involvement in both physiological processes, such as embryonic development and wound healing, and pathological conditions like tumor growth, metastasis, and inflammatory diseases. Its involvement in stimulating new blood vessel development is important to tumor growth. Understanding FLT1's intricate signaling pathways is paramount for developing targeted therapies against a spectrum of angiogenesis-dependent conditions, offering significant therapeutic potential.

Alternative Names

Fms related tyrosine kinase 1; VEGFR1; vascular endothelial growth factor receptor 1; fms related receptor tyrosine kinase 1; FLT; FLT-1; VEGFR-1; VEGFR1.

Background

This gene encodes a member of the vascular endothelial growth factor receptor (VEGFR) family. VEGFR family members are receptor tyrosine kinases (RTKs) which contain an extracellular ligand-binding region with seven immunoglobulin (Ig)-like domains, a transmembrane segment, and a tyrosine kinase (TK) domain within the cytoplasmic domain. This protein binds to VEGFR-A, VEGFR-B and placental growth factor and plays an important role in angiogenesis and vasculogenesis. Expression of this receptor is found in vascular endothelial cells, placental trophoblast cells and peripheral blood monocytes. Multiple transcript variants encoding different isoforms have been found for this gene. Isoforms include a full-length transmembrane receptor isoform and shortened, soluble isoforms. The soluble isoforms are associated with the onset of pre-eclampsia.[provided by RefSeq, May 2009].

Anti-FLT1 rAb Products

Creative Biolabs offers a comprehensive portfolio of anti-FLT1 recombinant antibodies, meticulously designed for exceptional specificity and affinity. Our products are generated using advanced recombinant technology, ensuring high batch-to-batch consistency and purity. These antibodies provide superior performance in various applications, enabling precise detection, neutralization, and modulation of FLT1 activity, thereby accelerating your research and drug discovery efforts with reliable results.

Cat. No. Product Name Target Species Host Species Applications
TAB-177 Anti-Human VEGFR-1 Recombinant Antibody (TAB-177) Human Human IgG1 - kappa IF, IP, Neut, FuncS, ELISA, FC, WB
ZG-0352J Mouse Anti-FLT1 Recombinant Antibody (ZG-0352J) Human Mouse IgG WB, ELISA
HPAB-1702-FY Human Anti-FLT1 Recombinant Antibody (clone 6F9) Human Human IgG1 ELISA, WB
HPAB-1703-FY Human Anti-FLT1 Recombinant Antibody (clone 13G12) Human Human IgG1 ELISA, WB
HPAB-1704-FY Human Anti-FLT1 Recombinant Antibody (clone 15F11) Human Human IgG1 ELISA, WB

Table 1. Featured anti-FLT1 recombinant antibody products at Creative Biolabs.

Creative Quality Control

At Creative Biolabs, every anti-FLT1 recombinant antibody undergoes stringent quality control measures to guarantee unparalleled performance. Our multi-faceted testing includes ELISA, Western Blot, flow cytometry, and functional assays to verify specificity, sensitivity, and biological activity. This dedication to rigorous validation guarantees that our antibodies constantly satisfy the highest industry standards, giving you confidence in your experimental results.

ELISA analysis. (Creative Biolabs Original)Fig.1 ELISA analysis of anti-VEGFR1 antibody
(Cat# TAB-177, Creative Biolabs).

WB analysis. (Creative Biolabs Original)Fig.2 WB analysis of anti-VEGFR1 antibody
(Cat# TAB-177, Creative Biolabs).

DB analysis. (Creative Biolabs Original)Fig.3 DB analysis of anti-VEGFR1 antibody
(Cat# TAB-177, Creative Biolabs).

WB analysis. (Creative Biolabs Original)Fig.4 WB analysis of anti-FLT1 antibody
(Cat# ZG-0352J, Creative Biolabs).

Customer Reviews

Excellent
We***l
Rabbit Anti-FLT1 Recombinant Antibody (VS3-CJ732) (VS3-CJ732)
Creative Biolabs' anti-FLT1 recombinant antibody has substantially simplified our angiogenesis research. The product documentation was really clear, and it worked effortlessly with our current procedures. The customer service personnel were also extremely attentive and knowledgeable, helping the entire transaction run smoothly and efficiently. We really endorse their stuff.
10/Nov/2024
Excellent
Lm***e
Anti-Human VEGFR-1 Recombinant Antibody (TAB-177) (TAB-177)
We've been continuously impressed with the performance of Creative Biolabs' anti-FLT1 antibody in our in vitro testing. Its excellent specificity and minimal background noise supplied us with extremely clean and accurate data, which was critical for our drug screening efforts. The uniformity among lots has also been a significant benefit, assuring repeatability in our long-term investigations.
5/Dec/2024
Excellent
Ke***i
Mouse Anti-FLT1 Recombinant Antibody (HPAB-2713LY) (HPAB-2713LY)
Our preclinical oncology investigations have profited significantly from Creative Biolabs' anti-FLT1 recombinant antibody. In our animal models, we observed effective suppression of tumor angiogenesis as well as a considerable decrease in tumor development. This antibody has proven to be an essential tool for confirming our treatment theories, hastening our progress toward clinical translation.
21/Mar/2025

rAb Production

Our anti-FLT1 recombinant antibodies are produced using state-of-the-art mammalian expression systems, ensuring native folding and optimal post-translational modifications. This advanced production platform allows for the generation of antibodies with superior biological activity and stability, free from common contaminants. Our streamlined processes guarantee consistent quality and timely delivery for your research needs.

Featured Anti-FLT1 Recombinant Antibody Production PlatformsMilligram-scale. (Creative Biolabs Original)
Fig.5 Milligram-scale anti-FLT1 recombinant antibody production.

Gram-scale. (Creative Biolabs Original)Fig.6 Gram-scale anti-FLT1 recombinant antibody production.

rAb Modalities

Creative Biolabs provides anti-FLT1 recombinant antibodies in a variety of species, formats, and conjugates. This diversity offers ideal appropriateness for a wide range of research applications, allowing for flexibility and complete solutions.

FLT1 antibody production and modalities. (Creative Biolabs Original)Fig.7 Full-length anti-FLT1 recombinant antibody production and modalities.

FLT1-Targeted Drug Information


Company Research phase Classification Condition
AstraZeneca (Originator)
ImClone (Lilly)
Innovent Biologics
Lilly
Shire (Originator)
Launched - 2014 Cancer Immunotherapy
Human Monoclonal Antibodies
Age-related macular degeneration (AMD)
Cancer
Cancer, biliary
Cancer, bladder (urothelial carcinoma, transitional cell)
Cancer, breast
Cancer, colorectal
Cancer, colorectal, metastatic
Cancer, fallopian tube
Cancer, gastroesophageal junction (adenocarcinoma)
Cancer, gastrointestinal
Cancer, kidney (renal cell carcinoma)
Cancer, liver
Cancer, liver (hepatocellular carcinoma)
Cancer, lung (non-small cell) (NSCLC)
Cancer, lung (non-small cell) (NSCLC), metastatic
Cancer, ovary
Cancer, ovary (epithelial recurrent)
Cancer, peritoneum
Cancer, prostate
Cancer, prostate, metastatic
Cancer, solid tumor
Cancer, stomach
Cancer, stomach, metastatic
Cancer, stomach (neuroendocrine)
Carcinoid tumor
Endometriosis
Female reproductive system cancer
Leukemia
Lymphoma, mantle cell
Melanoma, metastatic
Mesothelioma, malignant
Sarcoma, synovial
Tumor, desmoplastic small round cell
Allergan
Sirna Therapeutics (Originator)
Phase II Oligonucleotides
Small Interfering RNA (SiRNAs)
Macular degeneration
Wet macular degeneration (exudative)
Bristol-Myers Squibb
ImClone (Lilly)
Lilly (Originator)
Phase II Cancer Immunotherapy
Human Monoclonal Antibodies
Cancer, bladder (urothelial carcinoma, transitional cell)
Cancer, breast
Cancer, colorectal
Cancer, colorectal, metastatic
Cancer, kidney
Cancer, solid tumor
Actis Biologics
Chiron (Novartis Vaccines and Diagnostics)
Novartis Vaccines and Diagnostics
Sirna Therapeutics (Originator)
Phase II Ribozymes
Single-stranded oligoribonucleotide (RNA)
Cancer
Cancer, breast, metastatic
Cancer, colon
Cancer, colorectal, metastatic
Cancer, kidney (renal cell carcinoma)
Cancer, lung
Melanoma
Pieris Pharmaceuticals (Originator)
Pieris (Pieris Pharmaceuticals)
Syngenta
Phase I Polypeptides, from 41 AA
Recombinant proteins
Age-related macular degeneration (AMD)
Cancer, solid tumor
ImClone (Lilly)
Lilly
Opthea (Originator)
Phase I Cancer Immunotherapy
Human Monoclonal Antibodies
Cancer, solid tumor
ImClone (Lilly)
Lilly (Originator)
Phase I Cancer Immunotherapy
Chimeric Monoclonal Antibodies
Cancer, colorectal
Cancer, lung
Melanoma
Charlesson (Originator) Preclinical Gene Therapy
Peptides
Age-related macular degeneration (AMD)
BioWa (Originator) Preclinical Cancer Immunotherapy
Monoclonal Antibodies
Cancer, breast
Cancer, colon
University of Tokyo (Originator) Preclinical Cancer Immunotherapy
Cancer Vaccines
Peptides
Peptide Vaccines
Cancer
Lilly (Originator) Preclinical Cancer Immunotherapy
Murine Monoclonal Antibodies
Cancer
Other eye disorders
Avid Bioservices (Originator)
University of Texas at Dallas (UTD) (Originator)
Preclinical Cancer Immunotherapy
Monoclonal Antibodies
Cancer

(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)

Table 2. Public drug targeting FLT1.

Creative Biolabs is committed to advancing your scientific interests with our excellent anti-FLT1 recombinant antibody solutions. We are your reliable partner in promoting biological research and pharmaceutical development, thanks to our broad experience and devotion to excellence. Explore our extensive services and contact us now to see how our solutions can help you achieve your next breakthrough.

Go to compare

Go to compare

Happy Thanksgiving
Happy Thanksgiving close ad